TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14518703
Drug: Twice-a-day high-pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-a-day high-pill burden regimen (NFV+Combivir)
Study: 10606833
Drug: Inhaled rac-salbutamol
Normalized name: rac-dobutamine
DrugBank: Dobutamine (DB00841)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled rac-salbutamol (1200 microg) with oral charcoal
Study: 10606833
Drug: Intravenous rac-salbutamol
Normalized name: rac-dobutamine
DrugBank: Dobutamine (DB00841)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous rac-salbutamol (500 microg)
Study: 2868579
Drug: i.v. famotidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. famotidine 10 mg every 6-12 hours for maximally seven days
Study: 31146740
Drug: MCT oil
Normalized name: Organic MCT Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCT oil supplement (9% metabolic energy based calculated)
Study: 31146740
Drug: Control dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control dietary supplement (DS)
Study: 26455674
Drug: Imagery Rehearsal
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imagery Rehearsal Therapy (IRT) consisting of 6 individual sessions
Study: 18982437
Drug: 3-week oral
Normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-week oral anticoagulation therapy (OACs) before heparin bridging
Study: 18982437
Drug: No prior
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prior oral anticoagulation therapy (N-OACs)
Study: 14971670
Drug: Adrenaline and
Normalized name: Adrenaline and zinc only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline and saline infiltration (2.5 mg of 1:1000 adrenaline diluted in 500 mL of normal saline)
Study: 11801508
Drug: Latanoprost once
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Latanoprost once daily
Study: 11167277
Drug: Timolol plus
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol plus dorzolamide twice daily
Study: 28711629
Drug: Pre-procedure rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-procedure rectal swabs
Study: 23921338
Drug: PRP-augmented treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP-augmented treatment
Study: 19454547
Drug: Aprepitant (NK1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant (NK1 receptor antagonist)
Study: 19454547
Drug: Other NK1
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other NK1 receptor antagonists (under investigation)
Study: 15058213
Drug: Wenshen Xiezhuo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wenshen Xiezhuo Decoction (WSXZD) plus low-protein diets, controlling hypertension, and symptomatic treatment
Study: 15058213
Drug: Low-protein diets,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diets, controlling hypertension, and symptomatic treatment
Study: 2328561
Drug: Buprenorphine daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine daily administration (8 mg)
Study: 2328561
Drug: Buprenorphine alternate-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine alternate-day administration
Study: 28042054
Drug: Tight glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tight glycemic control with a blood glucose target range of 80-110 mg/dL (4.4-6.1 mmol/L)
Study: 28042054
Drug: Standard glycemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard glycemic control with a blood glucose target range of 150-180 mg/dL (8.3-10.0 mmol/L)
Study: 26747421
Drug: Probiotic milk
Normalized name: PROBIOTIC
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic milk (150 mL of milk supplemented with Lactobacillus rhamnosus SP1 at 10(7) CFU/mL)
Study: 24256479
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy with self-hypnosis (7 sessions)
Study: 24256479
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy without self-hypnosis (11 sessions)
Study: 17768103
Drug: Enzyme inhibitor
Normalized name: Enzyme inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme inhibitor Dx‐88
Study: 17768103
Drug: Receptor antagonist
Normalized name: H2-receptor antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receptor antagonist Icatibant
Study: 15831784
Drug: Azacitidine administered
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine administered as a single 75‐mg/m(2) SC dose
Study: 15831784
Drug: Azacitidine administered
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine administered as a single 75‐mg/m(2) IV infusion dose over 10 minutes
Study: 11979401
Drug: Margarine with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Margarine with sterol esters (MSE; 1.92 g/d)
Study: 11979401
Drug: Margarine with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Margarine with stanol esters (MSA; 1.76 g/d)
Study: 9882991
Drug: Rokitamycin, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rokitamycin, 400 mg tablet every 12 hours for 14 days
Study: 9882991
Drug: Josamycin, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Josamycin, 500 mg tablet every 8 hours for 14 days
Study: 8564679
Drug: Midazolam (3.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (3.4 +/- 1.3 mg)
Study: 30002871
Drug: Effective family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effective family planning (EFP) methods (injectable, oral, intra‐uterine contraceptive device, or Norplant)
Study: 27861326
Drug: Magnetic resonance-guided
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnetic resonance-guided laser-induced thermal therapy (MRgLITT)
Study: 30103529
Drug: Multiple micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrient (MMN) supplements
Study: 25065540
Drug: Chest Physical
Normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chest Physical Therapy (CPT)
Study: 20096799
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg od)
Study: 19029420
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Nurse‐Administered Symptom Management intervention
Study: 19029420
Drug: Single agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single agents chemotherapy
Study: 19029420
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy protocols
Study: 16497598
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch + stimulant medication
Study: 16497598
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch only
Study: 16497598
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch + stimulant medication
Study: 16497598
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch only
Study: 16497598
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch administration
Study: 10606836
Drug: Tolcapone (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolcapone (50, 200 or 400 mg three times daily)
Study: 9180124
Drug: High intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intensity exercise training (2 h of walking daily and four weekly sessions of high intensity monitored stationary cycling for 2 months)
Study: 1336886
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg epinephrine
Study: 3005138
Drug: Pectin (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pectin (12 g/day)
Study: 3005138
Drug: Cellulose (15
Normalized name: methylcellulose (15 CPS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cellulose (15 g/day)
Study: 3005138
Drug: Lignin (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignin (12 g/day)
Study: 29981576
Drug: Oxytocin administration
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin administration (30 IU in 1000 mL of Ringer's serum, max rate of 10 mL/min)
Study: 21373936
Drug: Lowering pCO(2)
Normalized name: Calendula Flower
DrugBank: Calendula officinalis flower (DB14263)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowering pCO(2) therapy
Study: 21373936
Drug: Raising pCO(2)
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raising pCO(2) therapy
Study: 16644317
Drug: Standard periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard periodontal therapy
Study: 12809583
Drug: Isoniazid 300
Normalized name: isoniazid 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid 300 mg once daily (Group 1)
Study: 12809583
Drug: Isoniazid 900
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid 900 mg/twice weekly (Group 2)
Study: 10852265
Drug: Thalidomide (initially
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (initially 100 mg daily, reduced to 50-25 mg daily for maintenance)
Study: 1739629
Drug: Carboplatin 400
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin 400 mg m‐2 alone (Arm A)
Study: 1739629
Drug: Carboplatin 300
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin 300 mg m‐2 with chlorambucil 10 mg day‐1 for 7 days (Arm B)
Study: 6748722
Drug: Reperfusion solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reperfusion solution (1 L delivered just prior to removal of the aortic clamp)
Study: 23662599
Drug: Firocoxib chewable
Normalized name: firocoxib Chewable Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Firocoxib chewable preparation
Study: 23088336
Drug: Lopinavir/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (LPV/r) 800/200 mg
Study: 23088336
Drug: Once-daily darunavir/ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily darunavir/ritonavir (DRV/r)
Study: 16391473
Drug: Cholinesterase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinesterase inhibitors (specific drugs not mentioned)
Study: 15288412
Drug: i.v. fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. fentanyl plus low dose i.v. ketamine (group 1)
Study: 15288412
Drug: Pre-operative low-dose
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative low-dose i.v. ketamine (group 1)
Study: 7969342
Drug: Parathyroid hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parathyroid hormone (40 micrograms subcutaneously daily)
Study: 7969342
Drug: Nafarelin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafarelin (200 micrograms intranasally twice daily)
Study: 7969342
Drug: Nafarelin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafarelin plus parathyroid hormone
Study: 3326689
Drug: Bay‐m‐1099 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bay‐m‐1099 (50 mg)
Study: 27060152
Drug: SMILE (dexamethasone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMILE (dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide)
Study: 8909331
Drug: Nadolol 120
Normalized name: nadolol 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol 120 mg/day
Study: 30855442
Drug: Sequential acupoint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential acupoint stimulation
Study: 29741592
Drug: SAFE (surgery,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAFE (surgery, antibiotics, facial cleanliness, and environmental improvement) interventions
Study: 25682077
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg daily for 1 week then 1 g twice daily for a further week)
Study: 25682077
Drug: Control (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (not receiving metformin)
Study: 20975299
Drug: 4 weeks
Normalized name: risperiDONE 75 mg/4 weeks intramuscular powder for injection, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 weeks of physical training with antioxidants (vitamin C 1,000 mg/day and vitamin E 400 IU/day)
Study: 15957827
Drug: Compound periploca
Normalized name: Periploca sepium root bark extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound periploca liquid (CPL)
Study: 15957827
Drug: Periploca syrup
Normalized name: Periploca sepium root bark extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periploca syrup
Study: 2031815
Drug: Atracurium 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.2 mg kg‐1 with previous suxamethonium 1 mg kg‐1
Study: 2031815
Drug: Atracurium 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.2 mg kg‐1 without previous suxamethonium
Study: 6382991
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 to 240 mg twice a day)
Study: 6382991
Drug: Verapamil (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (120 to 240 mg twice a day)
Study: 30202883
Drug: Nicorette 4
Normalized name: Nicorette 4mg Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorette 4 mg nicotine gum (NG)
Study: 20678689
Drug: Intranasal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal fentanyl 0.05 mg/0.1 mL
Study: 20678689
Drug: Placebo (preserved
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (preserved normal saline) 0.1 mL
Study: 20805137
Drug: Amniotic membrane
Normalized name: Amniotic Membrane Human Ophthalmic Sheet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amniotic membrane transplantation (AMT) in addition to conventional medical therapy
Study: 16193890
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose oral methylprednisolone
Study: 11890187
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day mianserin (n = 9)
Study: 29795314
Drug: Rescue antenatal
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue antenatal steroids (ideal treatment)
Study: 29795314
Drug: Rescue antenatal
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue antenatal steroids (remote treatment)
Study: 25582493
Drug: Cisplatin 75
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 75 mg/m² and pemetrexed 500 mg/m², every 3 weeks for 6 cycles followed by maintenance pemetrexed
Study: 25582493
Drug: Carboplatin AUC
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 6, paclitaxel 200 mg/m², and bevacizumab 15 mg/kg, every 3 weeks for 6 cycles followed by maintenance bevacizumab
Study: 10847254
Drug: Warfarin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin therapy with INR > 6.0
Study: 8664133
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (MA) at 160 mg day‐1
Study: 8664133
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (MA) at 320 mg day‐1
Study: 8664133
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (MA) at 320 mg day‐1 (further therapy)
Study: 8664133
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (MA) at 480 mg day‐1 (further therapy)
Study: 6740497
Drug: Anti-estrogen therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-estrogen therapy (tamoxifen, Nolvadex) added to chemotherapy (cyclophosphamide, methotrexate, and fluorouracil - CMF)
Study: 6740497
Drug: Nonspecific immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonspecific immunotherapy with bacillus Calmette-Guerin
Study: 29969366
Drug: Children with
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children with ALL treatment
Study: 29604548
Drug: Non-ablative Er:YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-ablative Er:YAG laser therapy
Study: 25304789
Drug: Synbiotic powder
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic powder containing Lactobacillus reuteri 10(8) CFU and 4.3 g of soluble fiber
Study: 17852417
Drug: Intravenous pregnanolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) during E2-only withdrawal
Study: 17852417
Drug: Intravenous pregnanolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) during withdrawal from E2 + P
Study: 7714935
Drug: Antimicrobial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial therapy (nalidixic acid)
Study: 7714935
Drug: Ineffective antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ineffective antimicrobial therapy
Study: 2665385
Drug: Mictonorm (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mictonorm (45 mg/d)
Study: 2665385
Drug: Spasuret (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spasuret (300 mg/d)
Study: 20917
Drug: Clobazam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobazam (10 mg)
Study: 1234503
Drug: Clobazam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobazam (20 mg)
Study: 20917
Drug: Triflubazam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triflubazam (20 mg)
Study: 20917
Drug: Triflubazam (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triflubazam (40 mg)
Study: 31482784
Drug: Vaccine awareness
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine awareness
Study: 17570424
Drug: Tolterodine ER
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine ER (4 mg QD)
Study: 9079242
Drug: Test preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test preparation (250 mg flutamide)
Study: 9079242
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation (250 mg flutamide)
Study: 8485068
Drug: Isradipine 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 1.25 mg bid for 4 weeks
Study: 8485068
Drug: Isradipine 2.5
Normalized name: isradipine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 2.5 mg bid for 4 weeks (if needed)
Study: 8485068
Drug: Isradipine (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (1.25 mg bid)
Study: 2875003
Drug: Methylprednisolone sodium
Normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone sodium succinate (MPSS) 30 mg/kg intravenous (maximum dose 3 g)
Study: 24658627
Drug: Lenvatinib 32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib 32 mg
Study: 20075789
Drug: Transthoracic echocardiography
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transthoracic echocardiography (TTE) with tri-iodothyronine +/- methylprednisolone therapy
Study: 20075789
Drug: Thyroid status
Normalized name: Thyroid
DrugBank: Thyroid, porcine (DB09100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid status and hormonal therapy
Study: 14685056
Drug: TMC125 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC125 monotherapy
Study: 14685056
Drug: Five-drug regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-drug regimen (zidovudine, lamivudine, abacavir, indinavir, nevirapine)
Study: 10590488
Drug: Electrophysiologically guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrophysiologically guided antiarrhythmic drug therapy
Study: 1308377
Drug: EMLA occluded
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA occluded with Orahesive Oral Bandages
Study: 6589647
Drug: Triamterene 200
Normalized name: Triamterene
DrugBank: Triamterene (DB00384)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamterene 200 mg/d
Study: 6589647
Drug: Amiloride 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride 15 mg/d
Study: 6589647
Drug: Acetazolamide 750
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide 750 mg/d
Study: 3539032
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of inhaled and oral salbutamol
Study: 3539032
Drug: Inhaled dry
Normalized name: Dry Powder Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled dry powder of salbutamol
Study: 12436150
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg)
Study: 26571889
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (massage therapy + magnetic sticking therapy at auricular points)
Study: 26571889
Drug: Simple massage
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple massage therapy
Study: 23127919
Drug: Inactivated virus
Normalized name: covid-19, inactivated virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated virus vaccine (one dose)
Study: 23127919
Drug: Inactivated virus
Normalized name: covid-19, inactivated virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated virus vaccine (two doses)